Gelteq Limited Ordinary Shares(GELS)

Drug Manufacturers - Specialty & Generic · Clayton, VIC

$0.58+0.04 (+6.67%)

Delayed quote: Oct 6, 2026, 11:28 AM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T15:42:00.352Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:42:00.352Z.

Quote observation: 2026-10-06T15:28:03.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 5,323,894
Total debt · period ending 2025-12-31: 3,412,541.5042
Cash · period ending 2025-12-31: 6,238.5877
TTM revenue · period ending 2025-12-31: N/A

FMP input reference: 6ebeba272bae7de15d59b23151f0025007a9c632b25eeddd13cd9ab927e6ebe5

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GELS EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

GELS Competitors' EV/Sales Ratio

GELS

Gelteq Limited Ordinary Shares

Current

Market Cap

$5.32M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALZN

Alzamend Neuro Inc

vs GELS

Market Cap

$5.29M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INBS

Intelligent Bio Solutions Inc.

vs GELS

Market Cap

$5.24M

EV/Sales Ratio

0.73x

TTM Avg

1.63x

3Y Avg

1.96x

5Y Avg

36.60x

PULM

Pulmatrix, Inc.

vs GELS

Market Cap

$5.22M

EV/Sales Ratio

N/A

TTM Avg

974.76x

3Y Avg

727.03x

5Y Avg

628.61x

LNAI

Lunai Bioworks Inc.

vs GELS

Market Cap

$5.21M

EV/Sales Ratio

165.70x

TTM Avg

289.54x

3Y Avg

289.54x

5Y Avg

289.54x

LIMN

Liminatus Pharma, Inc. Class A Common Stock

vs GELS

Market Cap

$5.16M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMNN

Imunon, Inc.

vs GELS

Market Cap

$5.11M

EV/Sales Ratio

N/A

TTM Avg

21.78x

3Y Avg

80.72x

5Y Avg

86.37x

BMGL

Basel Medical Group Ltd Ordinary Shares

vs GELS

Market Cap

$5.10M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACXP

Acurx Pharmaceuticals, Inc.

vs GELS

Market Cap

$5.59M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CALC

CalciMedica, Inc.

vs GELS

Market Cap

$4.94M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Gelteq Limited Ordinary Shares (GELS)	$5.32M	N/A	N/A	N/A	N/A
Alzamend Neuro Inc (ALZN)vs ›	$5.29M	N/A	N/A	N/A	N/A
Intelligent Bio Solutions Inc. (INBS)vs ›	$5.24M	0.73x	1.63x	1.96x	36.60x
Pulmatrix, Inc. (PULM)vs ›	$5.22M	N/A	974.76x	727.03x	628.61x
Lunai Bioworks Inc. (LNAI)vs ›	$5.21M	165.70x	289.54x	289.54x	289.54x
Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›	$5.16M	N/A	N/A	N/A	N/A
Imunon, Inc. (IMNN)vs ›	$5.11M	N/A	21.78x	80.72x	86.37x
Basel Medical Group Ltd Ordinary Shares (BMGL)vs ›	$5.10M	N/A	N/A	N/A	N/A
Acurx Pharmaceuticals, Inc. (ACXP)vs ›	$5.59M	N/A	N/A	N/A	N/A
CalciMedica, Inc. (CALC)vs ›	$4.94M	N/A	N/A	N/A	N/A

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics